IMU Biosciences
UK immune-profiling company extracting 100m+ data points from one blood sample.
IMU Biosciences closed a £40m funding round on 2 June 2026, oversubscribed and backed jointly by IQ Capital and Molten Ventures, to scale a technology that pulls over 100 million immune-system data points from a single blood sample. {{EVREF:/t/uk-startups-and-innovation/7/imu-raises-40m-to-read-blood}}
Last refreshed: 22 July 2026 · Appears in 1 active topic
How does IMU Biosciences extract 100 million immune data points from a single blood draw?
Timeline for IMU Biosciences
Mentioned in: Bank proposes £100m aerospace debt fund
UK Startups and InnovationMentioned in: Alchemab wins Bank's record £25m cheque
UK Startups and InnovationMentioned in: Jobs plan targets the lab-skills gap
UK Startups and InnovationMentioned in: Neubond seed is Japan VC's UK first
UK Startups and Innovationraised oversubscribed £40m Series A for immune diagnostics platform
UK Startups and Innovation: IMU raises £40m to read bloodBackground
IMU Biosciences builds immune-profiling technology, based in the UK, that turns one blood draw into more than 100 million data points describing a person's immune state, a scale of detail that would otherwise take several separate specialist tests and FAR more blood to gather.
That density of data matters because immune profiling sits where diagnostics, drug development and precision medicine overlap: spotting disease biomarkers, sorting patients into the right Arm of a clinical trial, tracking how someone responds to immunotherapy, and working out why one person's susceptibility to infection or autoimmune disease differs from another's all depend on reading the immune system in fine detail. Squeezing that reading down to a single tube changes the economics enough to make large-cohort research, and eventually everyday clinical testing, realistic rather than experimental.
Institutional backers underwrote that promise on 2 June 2026, closing an oversubscribed £40m ($53m) Series A led jointly by IQ Capital and Molten Ventures, with the British Business Bank investing alongside them. Reaching an oversubscribed round at this stage is notable in a sector where most companies are still years from proving the science works at all.
